gilead sciences annual report gilead annual report gilead sciences inc gilead sciences biopharmaceutical company discovers develops commercializes innovative therapeutics areas lakeside drive unmet medical need companys mission advance care patients suff ering lifethreatening diseases worldwide foster city california gilead operations countries worldwide headquarters foster city california ambisome cayston complera emtriva eviplera gilead gilead sciences gilead logo design harvoni hepsera letairis ranexa sovaldi stribild truvada tybost viread vistide vitekta volibris zydelig registered trademarks gilead sciences inc one related companies atripla registered trademark bristolmyers squibb gilead sciences llc lexiscan registered trademark astellas us llc tamifl u registered trademark hoff mannla roche inc macugen registered trademark eyetech inc f full us prescribing information gilead products available wwwgileadcom wwwgileadcomto stockholders employees friends made tremendous progress year introducing new authorization applications filed additional emerging therapies hepatitis c cancer continuing build developing market countries achievements hiv regulatory filings companys first course gileads medicines tenofovir alafenamide tafbased single tablet regimen str simultaneously gilead remains focused advancing care people united states european union forged new partnerships hcv development regimen potential expanded companys geographic reach include operations cure patients regardless genotype phase studies evaluating helped patients ever countries across six continents made strides combination gs sofosbuvir underway increase access medicines worldwide data anticipated third quarter moreover exploring gs pangenotypic protease inhibitor combination companys financial performance total revenues sofosbuvir gs potentially reduce treatment billion reflects ongoing focus scientific innovation duration less weeks delivers bestinclass medications patients diseases represent significant unmet needs around world hepatitis b virus hbv infection common cause liver cancer worldwide affects approximately million individuals viread continued innovation treatment liver diseases continues prescribed chronic hbv therapy united hepatitis crelated liver disease poses threat health millions states europe offering many patients effective approach people worldwide sovaldi important therapeutic advance managing disease taf nucleotide reverse transcriptase treatment chronic hepatitis c virus hcv received approval inhibitor designed prevent viral replication evaluated united states european union december phase studies enrollment completed january respectively today sovaldi approved countries end chronic hcv viread provides clear benefit chronic hbv sufferers however patients treated sovaldicontaining regimen since gileads ultimate goal offer patients cure product first approved biology hbv infection differs hcv developing cure require approach likely necessitate multiple drugs harvoni approved united states canada inhibit viral replication conjunction elimination hbv european union switzerland harvoni first oncedaily str dna infected liver cells treatment chronic hcv infection genotype patientsthe prevalent genotype worldwide consequently developing agents potentially enable immune system clear hbv infection phase studies underway harvoni represents significant medical advance treatment tlr agonist gs gs therapeutic hcv simple tolerable eliminates need vaccine also could used conjunction viread taf interferon ribavirin results high cure rates clinical trials oral therapies individuals genotype infection harvoni provided cure rates percent eight weeks oncedaily therapy within liver diseases area gilead also focusing nonalcoholic depending patients prior treatment history cirrhosis status steatohepatitis nash phase studies fully enrolled simtuzumab viral load gilead continues investigate use harvoni monoclonal antibody inhibits loxl nash well primary different patient groups including nongenotype infected patients sclerosing cholangitis early gilead also acquired farnesoid hiv coinfection patients advanced liver disease x receptor fxr program phenex comprising small molecule fxr agonists treatment liver diseases including nash united states company worked establish agreements additionally gileads ask inhibitor currently phase studies payers streamline process starting patient diabetic nephropathy pulmonary arterial hypertension therapy allowing patients begin therapy less time evaluated phase study nash slated begin first half spent authorization prescription reimbursement year three programs address liver damage nash patients via different mechanisms action europe gilead working governments across european union secure countrybycountry reimbursement quickly possi developing better options managing hiv ble based anticipated approvals sovaldi harvoni gileads oncedaily strs transformed treatment hiv company well prepared introduce products efficacy tolerability dosing convenience japan country one highest rates liver cancer due help people adhere medication important consid hcv industrialized world eration patients lifelong therapy clinical value strs broadly accepted within medical community result gilead also prioritizing access resourcelimited countries percent newlydiagnosed hiv patients united disease burden high gilead entered agreement states prescribed gilead str stribild eviplera egyptian government make sovaldi available complera us prescribed regimens first egyptian patients began treatment september also treatmentnave patients united states europe respectively september agreements established seven indian phar maceutical manufacturers allow manufacturing sovaldi groups across gilead working collaboratively help expand harvoni distribution developing countries access hiv testing linkage care infected estimated million people infected hepatitis c sovaldi virus data show diagnosis earlier treatment adherence help stem also approved india mongolia pakistan marketing spread disease nosellot ngised left right taiyin yang phd executive vice president pharmaceutical development manufacturing gregg h alton executive vice president corporate medical aff airs john mchutchison md executive vice president clinical research robin l washington executive vice president chief financial offi cer john f milligan phd president chief operating offi cer john c martin phd chairman chief executive offi cer norbert w bischofb erger phd executive vice president research development chief scientifi c offi cer katie l watson senior vice president human resources paul r carter executive vice president commercial operations andrew cheng md phd executive vice president hiv therapeutics development operations hiv patients live longer face additional health issues advancement cardiovascular respiratory disease financial highlights creating new hiv therapies potentially safer better areas cardiovascular respiratory diseases gilead tolerated achieve high efficacy rates remains priority focused expanding use available therapies developing compounds potential provide clinical benefit new patient gilead made exciting progress regimens containing taf populations key achievement area ambition taf demonstrated high antiviral efficacy improved renal trial potential change way patients pulmo bone safety profile results two phase studies showed nary arterial hypertension pah treated ambition evaluated compound known ecftaf elvitegravircobicistatemtricitabine ambrisentan approved letairis combination tadalafil tenofovir alafenamide favorable renal bone safety initial regimen pah patients data ambition showed profiles compared stribild encouraging results supported combination ambrisentan tadalafil resulted percent regulatory submissions ecftaf united states europe reduction risk clinical failure compared either drug prompted us accelerate regulatory filing timeline ftaf gilead submitted snda cover use ambrisentan emtricitabinetenofovir alafenamide important new combination tadalafil us fda december backbone address longterm treatment needs across many regimens also building knowledge gained finally gilead expanded partnership janssen rd ireland dis understanding mechanism action ranexa currently tribution partner compleraeviplera include development approved treatment chronic angina alters activity product sales total revenues commercialization rftaf ftaf plus janssens rilpivirine cardiac late sodium current gs potent selective late millions millions janssen also developing dcftaf contains janssens darunavir sodium current inhibitor development treat rare potentially would first proteasecontaining str available patients fatal heart conditions lack effective therapy long qt syndrome hypertrophic cardiomyopathy ventricular tachycardiaventricular ensure next generation tafbased regimens reach fibrillation patients around world expanded agreement medicines patent pool july speed access developing progress made gs investigational fusion inhibitor world approved united states agreement allow treatment respiratory syncytial virus rsv results phase sublicensing taf hbv hiv generic drug companies challenge study published new england journal india china manufacture distribute developing medicine indicate compound reduced symptoms viral countries agreement builds success earlier efforts load rsvinfected adult volunteers effective therapy today countries developing world included rsv accounts hospitalizations year gileads access program million hivinfected individuals united states simtuzumab studies several liver diseases developing world receiving one gileads antiretrovirals also evaluated potential treatment idiopathic pulmo representing percent people therapy nary fibrosis disease causes scarring reduced function lungs establishing foundation oncology antiviral products zydelig firstinclass pik delta inhibitor approved closing cardiopulmonary products united states european union several blood cancers remarkable year gilead enter portfolio products providing new therapy patient populations options marketed products diverse pipeline new partners zydelig provides foundation develop new cancer continued focus enabling worldwide access lifesaving therapies including combination regimens potentially offer cancer medications patients longer lasting remission rates earnings per share operating cash flow support shareholders guidance board millions conducting studies help us better understand potential directors incredible efforts employees responsible benefit zydelig variety lymphomas various stages companys success date allowing gilead achieve disease addition advancing development goal providing treatment millions individuals around world novel investigational anticancer molecules including syk inhibitor entospletinib gs jak inhibitor momelotinib thank interest gilead enhancing companys pipeline experimental oncology medicines gs btk inhibitor recently licensed ono pharmaceutical japan agreement gilead compounds targeting multiple signaling pathways associated bcell malignanciespik delta syk jak btk goal john c martin phd n duo en tg roa n dm ino gu nts may sum combination studies field oncology achieve chairman chief executive officer nongaap diluted earnings per share exclude aftertax pronounced durable response rates expand acquisitionrelated expenses restructuring expenses number cancers may treated stockbased compensation expenses forwardlooking statement nongaap diluted earnings per gaap diluted gs antimmp antibody undergoing evaluation ulcer annual report includes forwardlooking statements regarding clinical studies share exclude aftertax earnings ative colitis gastric pancreatic cancers based promising dn ed p loro pd mu ec nt tc man ild ei sd ta ot ne es n recl gu ud li tg rt yh e fil ia nn gt sic aip na dt e lad u nim chin eg sn ud c hc sh ti ae tv ee mm ee nn tst arf ec e pr rt ea din ic tions coc f q mu pi ei nt n ir ose ntl oa ecte xkd pb e e nx sp e ee sn os fe per share safety efficacy data anticipate moving compound forward involve risks uncertainties actual results may differ materially please refer nongaap diluted earnings per n dio lun eg da ea ap rnings clinical development ulcerative colitis gastric cancer gileads annual report year ended december attached ah ca qr ue f io tir n la e tex dcl u ed xe p ea nft se er st ax per share report risks uncertainties affecting gileads business gilead disclaims stockbased addition phase studies planned crohns disease obligation update forwardlooking statements report compensation expenses corporate information board directors senior leadership team brian j druker md corporate secretary john c martin phd john c martin phd director knight cancer institute gregg h alton chairman chief executive officer chairman chief executive officer associate dean oncology school executive vice president gilead sciences medicine corporate medical affairs john f milligan phd jeldwen chair leukemia john f cogan phd president chief operating officer research independent registered lead independent director oregon health science university public accountants gilead sciences norbert w bischofberger phd investigator howard hughes medical ernst young llp senior fellow hoover institution executive vice president institute redwood city california stanford university research development chief scientific officer mark c genovese md corporate headquarters etienne f davignon james w raitt endowed professor gilead sciences inc minister state belgium robin l washington medicine lakeside drive chairman genfina executive vice president codivision chief division foster city ca usa chief financial officer immunology rheumatology carla hills stanford university school medicine wwwgileadcom chair chief executive officer gregg h alton hills company international executive vice president robert harrington md stockholder inquiries consultants corporate medical affairs arthur l bloomfield professor inquiries stockholders medicine chair department potential investors regarding kevin e lofton fache paul r carter medicine stanford university company always welcome chief executive officer executive vice president school medicine receive prompt response please catholic health initiatives commercial operations direct requests information paul e klotman md john w madigan andrew cheng md phd president chief executive officer investor relations retired chairman executive vice president executive dean gilead sciences inc chief executive officer hiv therapeutics development john e clara b whitmore lakeside drive tribune company operations professor baylor college medicine foster city ca usa nicholas g moore john mchutchison md malcolm maccoss phd frsc retired global chairman executive vice president founder member bohicket information regarding gilead also pricewaterhousecoopers clinical research pharma consulting llc available wwwgileadcom visiting professor chemistry richard j whitley md taiyin yang phd medicine university oxford uk stock listing distinguished professor executive vice president exvice president drug discovery gilead common stock traded loeb scholar chair pediatrics pharmaceutical development sciences merck research nasdaq global select stock market professor pediatrics microbiology manufacturing laboratories rahway nj symbol gild medicine neurosurgery exgroup vice president chemistry university alabama birmingham katie l watson scheringplough research institute annual meeting senior vice president annual meeting stockholders gayle edlund wilson human resources john w mellors md held chairman emeritus cosmos professor medicine wednesday may westin california state summer school scientific advisory board chief division infectious diseases san francisco airport hotel math science joel r huff phd chairperson university pittsburgh school retired vice president medicine transfer agent registrar per woldolsen medicinal chemistry communications concerning stock retired president human health merck research laboratories eugene r schiff md transfer requirements lost certificates intercontinental division leonard miller professor medicine changes address merck co inc kenneth c anderson md dr nasser ibrahim alrashid chair directed transfer agent kraft family professor medicine schiff center liver diseases director emeritus gilead harvard medical school director schiff center liver computershare sciences board directors director lebow institute myeloma diseases po box george p shultz phd therapeutics director hepatology research college station tx distinguished fellow director jerome lipper multiple laboratory hoover institution myeloma center university miami miller school wwwcomputersharecominvestor stanford university danafarber cancer institute medicine equal opportunity employer paul berg phd robert schooley md gilead sciences proud cahill professor professor medicine head equal opportunity employer biochemistry emeritus division infectious diseases extends employment men stanford university school medicine vice chair department medicine women culturally diverse university california san diego backgrounds environment francis v chisari md respects individual differences professor head eric j topol md recognizes employee division experimental virology director scripps translational integral member company department immunology science institute workforce reflects values microbial science chief academic officer celebrates individuals scripps research institute scripps health make growing team professor genomics scripps research institute gilead sciences annual report gilead annual report gilead sciences inc gilead sciences biopharmaceutical company discovers develops commercializes innovative therapeutics areas lakeside drive unmet medical need companys mission advance care patients suff ering lifethreatening diseases worldwide foster city california gilead operations countries worldwide headquarters foster city california ambisome cayston complera emtriva eviplera gilead gilead sciences gilead logo design harvoni hepsera letairis ranexa sovaldi stribild truvada tybost viread vistide vitekta volibris zydelig registered trademarks gilead sciences inc one related companies atripla registered trademark bristolmyers squibb gilead sciences llc lexiscan registered trademark astellas us llc tamifl u registered trademark hoff mannla roche inc macugen registered trademark eyetech inc f full us prescribing information gilead products available wwwgileadcom wwwgileadcom gilead sciences annual report gilead annual report gilead sciences inc gilead sciences biopharmaceutical company discovers develops commercializes innovative therapeutics areas lakeside drive unmet medical need companys mission advance care patients suff ering lifethreatening diseases worldwide foster city california gilead operations countries worldwide headquarters foster city california ambisome cayston complera emtriva eviplera gilead gilead sciences gilead logo design harvoni hepsera letairis ranexa sovaldi stribild truvada tybost viread vistide vitekta volibris zydelig registered trademarks gilead sciences inc one related companies atripla registered trademark bristolmyers squibb gilead sciences llc lexiscan registered trademark astellas us llc tamifl u registered trademark hoff mannla roche inc macugen registered trademark eyetech inc f full us prescribing information gilead products available wwwgileadcom wwwgileadcom